Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Sometimes the older formulation of tenofovir is a better choice for HIV prevention.
A new simulation suggests that by 2030, multimorbidity in people with HIV will rise substantially.
Researchers sought to model the future rates of conditions such as chronic kidney disease and high blood pressure among people with HIV.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
This finding held true even when the researchers restricted their analysis to caffeine from soft drinks.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
Researchers urge clinicians to closely monitor their patients with HIV and chronic kidney disease.
Among the hep C population, other factors associated with chronic kidney disease include being older and having diabetes or HIV.
Researchers found that those with a greater than 5 percent five-year risk of either condition also had a high risk of the other.
Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.
The two-drug regimen can cure the virus in as little as eight weeks.
Real-world data showed Merck’s hep C regimen performed well among a population with genotypes 1 or 4 and multiple other health conditions.
A meta-analysis of major clinical trials of hepatitis C treatments identified various subgroups who have unmet needs.
As the HIV population becomes older, an expanding proportion will need treatment for age-related conditions, which will make caring for...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.